{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:34:50Z","timestamp":1786977290660,"version":"build-2736575974"},"reference-count":121,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Antibody\u2010drug conjugates (ADCs) are innovative drugs composed of cytotoxic molecules (payload) linked to antibodies, that selectively target and kill cancer cells upon internalization. In\u00a0vivo, ADCs exist as intact molecules, naked antibodies, or released, unconjugated (linker\u2010)payload. Accurate quantification of these entities is crucial for understanding ADCs pharmacokinetics. Ligand\u2010binding assays are commonly used to measure ADC concentrations and total antibody concentrations, whereas LC\u2013MS\/MS is used to analyze the payload. Due to limitations in ligand\u2010binding assays, this review focuses on quantitative LC\u2013MS methods for the different ADC entities. Quantitative LC\u2013MS assays were described for all ADC entities, available from full manuscripts and regulatory reviews of 12 ADCs evaluated by the European Medicine Agency, by January 2025. The review summarized sample pre\u2010treatment, chromatography, mass spectrometry, validation, and stability data for each LC\u2013MS method. Overall, critical details were often missing, particularly concerning sample pre\u2010treatment, validation criteria, and sample stability. In conclusion, LC\u2013MS quantification of ADC entities is feasible but current methods lack sufficient detail. Our review highlights the need for further research to develop reliable LC\u2013MS assays for ADCs. This review may serve as a starting point and outlines key factors to consider in future LC\u2013MS method development.<\/jats:p>","DOI":"10.1002\/bmc.70334","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:39:13Z","timestamp":1767854353000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An Overview of Liquid Chromatography\u2013Mass Spectrometry (LC\u2013MS) Methods for the Quantification of Antibody\u2010Drug Conjugates"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6542-3618","authenticated-orcid":false,"given":"Pauline\u00a0L.\u00a0M.","family":"Buitelaar","sequence":"first","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology Antoni van Leeuwenhoek Hospital\/the Netherlands Cancer Institute  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology Antoni van Leeuwenhoek Hospital\/the Netherlands Cancer Institute  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00a0H.","family":"Beijnen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology Antoni van Leeuwenhoek Hospital\/the Netherlands Cancer Institute  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Division of Medical Oncology the Netherlands Cancer Institute  Amsterdam the Netherlands"},{"name":"Department of Medical Oncology University Medical Centre Utrecht, Utrecht University  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin\u00a0D.\u00a0R.","family":"Huitema","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology Antoni van Leeuwenhoek Hospital\/the Netherlands Cancer Institute  Amsterdam the Netherlands"},{"name":"Department of Clinical Pharmacy University Medical Center Utrecht, Utrecht University  Utrecht the Netherlands"},{"name":"Department of Pharmacology Princess M\u00e1xima Center for Pediatric Oncology  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11113080"},{"key":"e_1_2_10_3_1","unstructured":"BC Cancer Drug Manual. \u201cDrug Name: Inotuzumab Ozogamicin.\u201d Retrieved June 24 2025.http:\/\/www.bccancer.bc.ca\/drug\u2010database\u2010site\/Drug%20Index\/Inotuzumab%20ozogamicin_monograph.pdf."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.268"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.10.021"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp500798y"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2024.342537"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2024.2302460"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.09.016"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.Cd\u201024\u20100708"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2022.123215"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.13.72"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1156829"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571\u2010021\u201000470\u20108"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573\u2010023\u201000709\u20102"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.Can\u201005\u20104489"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells13050459"},{"key":"e_1_2_10_18_1","unstructured":"European Medicines Agency. \u201cAdcetris.\u201d Retrieved November 23 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/adcetris."},{"key":"e_1_2_10_19_1","unstructured":"European Medicines Agency. \u201cAssesment Report\u2014BLENREP.\u201d Retrieved November 28 2023.https:\/\/www.ema.europa.eu\/en\/documents\/assessment\u2010report\/blenrep\u2010epar\u2010public\u2010assessment\u2010report_en.pdf."},{"key":"e_1_2_10_20_1","unstructured":"European Medicines Agency. \u201cAssessment Report\u2014PADCEV.\u201d Retrieved November 27 2023.https:\/\/www.ema.europa.eu\/en\/documents\/assessment\u2010report\/padcev\u2010epar\u2010public\u2010assessment\u2010report_en.pdf."},{"key":"e_1_2_10_21_1","unstructured":"European Medicines Agency. \u201cAssessment Report\u2014POLIVY.\u201d Retrieved November 28 2023.https:\/\/www.ema.europa.eu\/en\/documents\/assessment\u2010report\/polivy\u2010epar\u2010public\u2010assessment\u2010report_en.pdf."},{"key":"e_1_2_10_22_1","unstructured":"European Medicines Agency. \u201cAssessment Report\u2014TRODELVY.\u201d Retrieved November 28 2023.https:\/\/www.ema.europa.eu\/en\/documents\/assessment\u2010report\/trodelvy\u2010epar\u2010public\u2010assessment\u2010report_en.pdf."},{"key":"e_1_2_10_23_1","unstructured":"European Medicines Agency. \u201cAssessment Report\u2014ZYNLONTA.\u201d Retrieved November 28 2023.https:\/\/www.ema.europa.eu\/en\/documents\/assessment\u2010report\/zynlonta\u2010epar\u2010public\u2010assessment\u2010report_en.pdf."},{"key":"e_1_2_10_24_1","unstructured":"European Medicines Agency. \u201cBesponsa.\u201d Retrieved November 23 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/besponsa."},{"key":"e_1_2_10_25_1","unstructured":"European Medicines Agency. \u201cBlenrep.\u201d Retrieved November 23 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/blenrep."},{"key":"e_1_2_10_26_1","unstructured":"European Medicines Agency. \u201cEnhertu.\u201d Retrieved November 23 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/enhertu."},{"key":"e_1_2_10_27_1","unstructured":"European Medicines Agency. \u201cKadcyla.\u201d Retrieved November 23 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kadcyla."},{"key":"e_1_2_10_28_1","unstructured":"European Medicines Agency. \u201cMylotarg.\u201d Retrieved November 23 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mylotarg\u20100."},{"key":"e_1_2_10_29_1","unstructured":"European Medicines Agency. \u201cPadcev.\u201d Retrieved November 23 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/padcev."},{"key":"e_1_2_10_30_1","unstructured":"European Medicines Agency. \u201cPolivy.\u201d Retrieved November 23 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/polivy."},{"key":"e_1_2_10_31_1","unstructured":"European Medicines Agency. \u201cSummary of Product Characteristics\u2014ADCETRIS.\u201d Retrieved November 27 2023.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/adcetris\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_32_1","unstructured":"European Medicines Agency. \u201cSummary of Product Characteristics\u2014BESPONSA.\u201d Retrieved November 23 2023.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/besponsa\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_33_1","unstructured":"European Medicines Agency. \u201cSummary of Product Characteristics\u2014BLENREP.\u201d Retrieved November 28 2023.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/blenrep\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_34_1","unstructured":"European Medicines Agency. \u201cSummary of Product Characteristics\u2014ENHERTU.\u201d Retrieved November 27 2023.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/enhertu\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_35_1","unstructured":"European Medicines Agency. \u201cSummary of Product Characteristics\u2014KADCYLA.\u201d Retrieved November 23 2023.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/kadcyla\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_36_1","unstructured":"European Medicines Agency. \u201cSummary of Product Characteristics\u2014MYLOTARG.\u201d Retrieved November 27 2023.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/mylotarg\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_37_1","unstructured":"European Medicines Agency. \u201cSummary of Product Characteristics\u2014PADCEV.\u201d Retrieved November 27 2023.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/padcev\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_38_1","unstructured":"European Medicines Agency. \u201cSummary of Product Characteristics\u2014POLIVY.\u201d Retrieved November 28 2023.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/polivy\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_39_1","unstructured":"European Medicines Agency. \u201cSummary of Product Characteristics\u2014TRODELVY.\u201d Retrieved November 28 2023.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/trodelvy\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_40_1","unstructured":"European Medicines Agency. \u201cSummary of Product Characteristics\u2014ZYNLONTA.\u201d Retrieved November 28 2023.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/zynlonta\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_41_1","unstructured":"European Medicines Agency. \u201cTrodelvy.\u201d Retrieved November 23 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trodelvy."},{"key":"e_1_2_10_42_1","unstructured":"European Medicines Agency. \u201cZynlonta.\u201d Retrieved November 23 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zynlonta."},{"key":"e_1_2_10_43_1","unstructured":"FDA U.S. Food & Drug Administration. \u201cDrugs@FDA.\u201d Drug Approval Package\u2014Mylotarg (Gemtuzumab Ozogamicin) Injection. Retrieved May 3 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/21174_Mylotorg.cfm."},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1433973"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392\u2010022\u201000947\u20107"},{"key":"e_1_2_10_46_1","unstructured":"Gilead Medical Information. \u201cTrodelvy Storage and Stability (Reconstituted and Diluted).\u201d Retrieved June 24 2025.https:\/\/www.askgileadmedical.com\/docs\/trodelvy\/trodelvy\u2010storage\u2010and\u2010stability\u2010reconstituted\u2010and\u2010diluted."},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010011\u20101817\u20103"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.13.38"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0891\u20105849(99)00176\u20108"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1039\/c6sc05149a"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010023\u201001834\u20103"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416\u2010019\u20100635\u2010y"},{"key":"e_1_2_10_53_1","unstructured":"Immunogen. \u201cInvestors & Media\u2014ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum\u2010Resistant Ovarian Cancer.\u201d Retrieved December 13 2023.https:\/\/investor.immunogen.com\/news\u2010releases\/news\u2010release\u2010details\/immunogen\u2010announces\u2010european\u2010medicines\u2010agency\u2010acceptance."},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419\u2010022\u201004912\u20108"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.06.032"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095\u2010015\u20101657\u20107"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030756"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio\u20102018\u20100003"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2022.13.1.7"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541\u20107786.Mcr\u201019\u20100582"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.Mct\u201022\u20100375"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1021\/bc300491k"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/chem.200700504"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2004.11.004"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2024.14356"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.01.011"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12482"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.3390\/antib10020020"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935\u2010022\u201002679\u20108"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio\u20102021\u20100171"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248\u2010014\u20109710\u20108"},{"key":"e_1_2_10_72_1","unstructured":"NCI Drug Dictionary. \u201cfam\u2010trastuzumab deruxtecan\u2010nxki.\u201d Retrieved September 3 2024.https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer\u2010drug\/def\/trastuzumab\u2010deruxtecan."},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010023\u201004575\u2010y"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00044\u2010023\u201003177\u2010w"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27196299"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1345"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12660"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010024\u201001366\u20103"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1795492"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42004\u2010024\u201001297\u2010x"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_390094"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-13081-1_1"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020396"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.9b00437"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1080\/14786410412331299005"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.367"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1021\/bc800059t"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2394"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.03.042"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-13081-1_2"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9101111"},{"key":"e_1_2_10_93_1","unstructured":"ThermoFisherScientific. \u201cOverview of Affinity Purification.\u201d Retrieved May 30 2025.https:\/\/www.thermofisher.com\/nl\/en\/home\/life\u2010science\/protein\u2010biology\/protein\u2010biology\u2010learning\u2010center\/protein\u2010biology\u2010resource\u2010library\/pierce\u2010protein\u2010methods\/overview\u2010affinity\u2010purification.html."},{"key":"e_1_2_10_94_1","unstructured":"Tivdak. \u201cMechanism of Action\u2014Tivdak: The First\u2010and\u2010Only Antibody\u2010Drug Conjugate (ADC) for Adults with Previously Recurrent or Metastatic Cervical Cancer.\u201d Retrieved December 14 2023.https:\/\/www.tivdakhcp.com\/about\u2010tivdak\/."},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.112991"},{"key":"e_1_2_10_96_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26195847"},{"key":"e_1_2_10_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13238\u2010016\u20100323\u20100"},{"key":"e_1_2_10_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571\u2010023\u201000850\u20102"},{"key":"e_1_2_10_99_1","unstructured":"U.S. Food & Drug Administration. \u201cDrug Approval Package: ADCETRIS\u2014Multi\u2010Discipline Review.\u201d Retrieved January 22 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/125388Orig1s000ClinPharmR.pdf."},{"key":"e_1_2_10_100_1","unstructured":"U.S. Food & Drug Administration. \u201cDrug Approval Package: BESPONSA\u2014Multi\u2010Discipline Review.\u201d Retrieved January 8 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761040Orig1s000MultidisciplineR.pdf."},{"key":"e_1_2_10_101_1","unstructured":"U.S. Food & Drug Administration. \u201cDrug Approval Package: ELAHERE\u2014Multi\u2010Discipline Review.\u201d Retrieved January 4 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/761310Orig1s000MultidisciplineR.pdf."},{"key":"e_1_2_10_102_1","unstructured":"U.S. Food & Drug Administration. \u201cDrug Approval Package: ENHERTU\u2014Multi\u2010Discipline Review.\u201d Retrieved December 22 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761139Orig1s000MultidisciplineR.pdf."},{"key":"e_1_2_10_103_1","unstructured":"U.S. Food & Drug Administration. \u201cDrug Approval Package: KADCYLA\u2014Clinical Pharmacology and Biopharmaceutics Review(s).\u201d Retrieved February 13 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/125427Orig1s000ClinPharmR.pdf."},{"key":"e_1_2_10_104_1","unstructured":"U.S. Food & Drug Administration. \u201cDrug Approval Package: PADCEV\u2014Multi\u2010Discipline Review.\u201d Retrieved January 5 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761137Orig1s000MultiDiscliplineR.pdf."},{"key":"e_1_2_10_105_1","unstructured":"U.S. Food & Drug Administration. \u201cDrug Approval Package: POLIVY\u2014Multi\u2010Discipline Review.\u201d Retrieved January 5 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761121Orig1s000ClinPharmR.pdf."},{"key":"e_1_2_10_106_1","unstructured":"U.S. Food & Drug Administration. \u201cDrug Approval Package: TIVDAK\u2014Multi\u2010Discipline Review.\u201d Retrieved January 4 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/761208Orig1s000MultidisciplineR.pdf."},{"key":"e_1_2_10_107_1","unstructured":"U.S. Food & Drug Administration. \u201cDrug Approval Package: TRODELVY\u2014Multi\u2010Discipline Review.\u201d Retrieved January 8 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/761115Orig1s000MultidisciplineR.pdf."},{"key":"e_1_2_10_108_1","unstructured":"U.S. Food & Drug Administration. \u201cDrug Approval Package: ZYNLONTA\u2014Multi\u2010Discipline Review.\u201d Retrieved January 4 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/761196Orig1s000MultidisciplineR.pdf."},{"key":"e_1_2_10_109_1","unstructured":"U.S. Food & Drug Administration. \u201cHighlights of Prescribing Information\u2014ELAHERE.\u201d Retrieved December 14 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761310s000lbl.pdf."},{"key":"e_1_2_10_110_1","unstructured":"U.S. Food & Drug Administration. \u201cHighlights of Prescribing Information\u2014TIVDAK.\u201d Retrieved December 14 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761208Orig1s000lbledt.pdf."},{"key":"e_1_2_10_111_1","unstructured":"U.S. Food & Drug Administration (FDA). \u201cHighlights of Prescribing Information\u2014ENHERTU.\u201d Retrieved November 28 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761139s021lbl.pdf."},{"key":"e_1_2_10_112_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.20230"},{"key":"e_1_2_10_113_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520"},{"key":"e_1_2_10_114_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco\u201025\u201001235"},{"key":"e_1_2_10_115_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010024\u201001386\u2010z"},{"key":"e_1_2_10_116_1","unstructured":"WuXiAppTec. \u201cAntibody\u2010Drug Conjugate (ADC) Bioanalysis Strategies Based on LC\u2010MS.\u201d Retrieved May 30 2025.https:\/\/dmpkservice.wuxiapptec.com\/articles\/13\u2010antibody\u2010drug\u2010conjugate\u2010adc\u2010bioanalysis\u2010strategies\u2010based\u2010on\u2010lc\u2010ms\/."},{"key":"e_1_2_10_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2011.01.004"},{"key":"e_1_2_10_118_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2096"},{"key":"e_1_2_10_119_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.4c03383"},{"key":"e_1_2_10_120_1","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.S150317"},{"key":"e_1_2_10_121_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.6.17922"},{"key":"e_1_2_10_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2020.05.008"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.70334","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bmc.70334","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.70334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T03:55:06Z","timestamp":1769831706000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.70334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":121,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/bmc.70334"],"URL":"https:\/\/doi.org\/10.1002\/bmc.70334","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"2025-08-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70334"}}